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I. INTRODUCTION 
In 1987, Ochiai and coworkers reported the im-
munosuppressive qualities of a new immuno-
suppressive agent, FK506, isolated from the fer-
mentation broth of a soil fungus, Streptomyces 
tsukubaensis (1). Extensive in vitro studies, 
demonstrated the effectiveness in suppressing 
mixed lymphocyte cultures, presumably by in-
hibiting IL-2 synthesis following alloactivation 
(2). The receptor for FK506 has been identified, 
and has been characterized as a peptidyl-prolyl 
cis-trans isomerase (3). 
The background for the clinical development of 
FK506 was well documented by Starzl in the 
opening remarks of a satellite symposium on 
FK506, held in Barcelona, Spain in November, 
1989, as part of the European Society of Organ 
Transplantation (4). In vivo studies using a 
number of animal models have shown a 
marked ability to prevent rejection following 
various types of organ transplants (5-7). More 
interestingly, FI<506 possess the ability to re-
verse ongoing rejection in animal models (7-8). 
This characteristic is unique, since it is well 
known that cyclosporine will not reverse estab-
lished ongoing rejection. These properties 
served as the initiative to pursue clinical testing 
ofFI<506. 
The objective of this manuscript is to update 
the reader on the current status of the use of 
FI<506 in human organ transplantation, at the 
University of Pittsburgh. We will attempt to 
summarize the results of "rescue" therapy and 
"primary" therapy with FK506 in human liver 
(9,10), kidney (11 ) and heart (12) transp!:-!lta-
tion. 
II. METHODS 
1. Study Design 
The trials in liver, kidney and heart transplanta-
tion were conducted at the University of 7':tts-
burgh, Presbyterian University Hospital, Oill-
dren's Hospital of Pittsburgh and the Veterans 
Administration Medical Center, with the ap-
proval of the respective Institutional Review 
Boards. Informed consent was obtained from 
patients or their appointed guardians. 
2. Patient Profiles 
In the liver study, patients were treated ",vith 
F1<506 as part of two studies, one being the res-
cue study, in which 57 patients were entered 
for the diagnosis of acute rejection, while 116 
patients were converted from cyclosporine to 
FK506 for chronic rejection. In the primary liver 
transplant group, 125 patients were treated 
with FK506 and low dose steroids, as the base-
line immunosuppression following liver trans-
plantation. 
In the kidney study, patients were treated with 
F1<506 as part of two studies, one being the res-
cue study, in which 21 patients were entered 
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for the diagnosis of rejection. In the primary 
kidney transplant group, 65 patients were treat-
ed with FI<506 and low dose steroids, as the 
baseline immunosuppression following kidney 
transplantation. 
In the heart study, patients were also divided 
into two studies. In one group, 30 patients were 
treated with FK506 as primary immunosup-
pression, while in the second group, 10 patients 
were converted to FI<506 because of pel"Sistent 
rejection. 
3. Diagnostic evaluations 
For patients who were experiencing organ dys-
function, the final catagOrization of dysfunction 
was based upon clinical, biochemical and/or 
rustopathologic findings. For all patients, either 
as primary or as rescue therapy, cause(s) of or-
gan dysfunction were carefully sought for, the 
workup being customized to the organ trans-
planted. Ultrasonic determination of vessel pa-
tency and radiographic evaluation of the biliary 
· or urinary system were used to rule out a tech-
nical or mechanical defect. Angiography was 
performed when indicated. Appropriate viral 
· cultures and stains were used to detect viral in-
fections. 
Protocol biopsies were utilized in the evalua-
:. tion of efficacy of FK 506 therapy. All biopsies 
were blinded interpreted by a single experi-
· enced liver pathologist (AID). Biopsy sped-
~ mens were fixed in neutral buffered formalin 
and routinely stained with hematoxylin and e0-
sin, trichrome and reticulin stains. The criteria 
· us-~ for pathologic diagnosis have been dearly 
: defined in previous reports (13,14). 
_ 4. Timing and details 01 therapy 
Initiation of treatment with FK 506 was done in 
the hospital and was given initially as a paren-
. teral dose, followed by conversion to an oral 
· dose. The inital parenteral dose of FI<506 was 
0.075 to 0.15 mg/kg, given intravenously over a 
· period of four hours. This was continued until 
: the patient was able to ingest the oral form of 
· FKs06. Generally, oral dosages of FK506 were 
. given at 0.30 mg/kg/d, given in two divided 
.', doses. Dose adjustments of FK506 were based 
'J! 
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upon monitoring of serum trough levels by EL-
ISA (15) to achieve a 12 hour trough level of 1.0 
ng/ml, and also by adjustment according to . 
clinical or biochemical parameters. 
5. Evaluation 01 response 
Periodic determinations of liver and kidney 
functions, including total bilirubin (TBIL), ser-
um glutamic transaminases, SGOT and SGPT, 
alk.aIine phosphatase, blood urea nitrogen 
(BUN) and serum creatinine were performed. 
All values are expressed as the value plus/ 
minus one standard deviation. Protocol biop-
sies were obtained after initiation of FI<S06 
therapy. 
III. RESULTS 
1. Liver Transplantation 
a) Rescue Therapy 
In this population of 173 patients, in whom 
many were critically ill at the time of FI<S06 
conversion, a total of 14 deaths were encoun-
tered (8.1 %). The causes of death were numer-
ous, but the incidence of mortality was directly 
correlated with the medical condition of the pa-
tient at the time of FI<506 conversion. Sepsis 
was the cause of death in 4 patients. Three pa-
tients died of hemorrhagiC complications. Three 
patients died of metastatic carcinoma following 
transplantation. In two patients, retransplanta-
tion was not considered an option for the fail-
ing liver allograft. One patient was started on 
~ 506 with pathologic findings of late chronic 
rejection, and died of technical causes during 
an attempted retransplantation. In one case, no 
cause of death could be determined. This pa-
tient died at home and had been off of FI<S06 
for four months when she died. 
The biochemical response of the liver allografts 
to FK506 was analyzed by classifying patients 
either into acute or chronic rejection, dependent 
upon the principle histopathologic findings. 
For the 57 patients who were treated for acute 
rejection, documented on liver biopsy or as 
judged by biochemical and clinical parameters, 
the TBIL, SGOT, and SGPT values, prior to 
FK506 were: 4.68 i 5.91 mg/dl, 240 ± 431 lU/L, 
and 292 ± 383 lUlL, respectively. These values 
fell, by the sixth month, to: 0.76 ± 1.41 mgt dl, 
98 ± 163 ill IL, and 90 ± 128 IV /L, respectively. 
Patients with an entrance diagnosis of chronic 
rejection also had a beneficial response to 
FK506. For the 116 patients treated for this spe-
cific indication, the total bilirubin fell to nonnal 
values (pre-FK506, 5 07 ± 8.16 mg/dl; 6 months, 
0.99 ± 1.47 mg/dl) while the average transami-
nase values were still slightly elevated above 
nonnal values (pre-FI<506, SCOT /SGPT, 200 ± 
175 IU/L/275 ± 223 lUlL; 6 months, scar / 
SGPT, 44 ± 72 IV/VIOl ± 68 IV/L). 
In each case where histopathologic changes 
were predominant, the influence of FK506 on 
the initial findings of rejection or hepatitis 
could be evaluated in serial followup biopsies. 
Overall, 17% of biopsies with a diagnosis of re-
jection showed worsening of the pathology. 
36% of liver biopsies showed no patholOgiC 
changes between the pre-FKS06 biopsy and the 
two month followup biopsy. 47% of the remain-
ing biopsies showed improverpent between the 
initial and followup biopsies. These changes 
were particularly impressive in patients whose 
pretreatment biopsies contained bile duct le-
sions that generally progress to bile duct disap-
pearance and graft loss, in spite of intensive im-
munosuppression. 
b) Primary Therapy 
Ten of the patients have died, leaving an actual 
survival of 92%. The followup period was be-
tween 6 and 12 months. When compared to 325 
sequential liver transplants during the preceed-
ing year prior to FI<506, the results are statisti-
cally significantly better in terms of patient and 
graft survival, in which the 6 month survival 
was 79%. This trend was seen in both the adult 
population (110 patients) and in the pediatric 
population (15 patients), although the numbers 
of pediatric patients in the trial were too small 
to achieve statistical significance. Of the ten 
deaths, five were due to sepsis, one to heart fail-
ure, one to a cerebral vascular acddent, two to 
non-reversible hepatic coma, and one to techni-
cal complications. 
During the followup period, 50% of all r~ 
ients were taken off steroids and were mai 
tained on single drug immunosuppression Wi 
FI<506. Yet 52.8% of all patients were rejectic 
free during the entire period of study. The ll\ 
jority of rejection episodes were mild and we 
easily controlled with a single dose of bolt 
steroids (either methylprednisolone or hydr( 
cortisone). Only 17.8% of the rejection episoo( 
require further steroid treatment in the fonn ( 
a steroid taper or additional steroid boiI~sK I 
addition, only 11.2% of the' patients require 
OKT3. 
The incidence of serious infections, in spite c 
the potency of FKS06, has not appeared to b 
alarming. The incidence of serious infection 
was about 50% less than seen with a historica 
group of patients given cyclosporine. Of note, i 
that the incidence of cytomegalovirus irue:tion: 
did not appear to be increased, when co:". ,.;.-:arec 
to patients on cyc1osporine. 
2. Kidney Transplantation 
a) Rescue Therapy 
A total of 21 patients were converted from cy' 
c1osporine based immunosuppression to FI<506 
based immunosuppression for persistent kid-
ney rejection. No deaths were encounte"':d. Of 
the 21 patients, 10 were classified into la;.; rejec-
tion episodes (>60 days), while 11 were treated 
early in the post-transplant course «60 days). 7 
of the 11 early rescues were successful, in con-
trast to only 4 of 10 late rescues. Most of the 
failures of FK506 rescue therapy in this group 
of patients were in patients who had chronic 
glomerulosclerosis and chronic rejection on bi-
opsy, prior to FK506 rescue. In those patients 
with acute cellular rejection, the result!, were 
better. The serum creatinine at the time of con-
version, was also correlated with the success of 
therapy. 4 of 5 (80%) patients with a serum 
creatinine <3.0 mgldl have good. renal func-
tion, while only 7 of 16 (44%) patients with a 
pre-conversion serum creatinine >3.0 mg/dl 
have a functiOning kidney. The overall serum 
crea tinine prior to FK506 con version in the 11 
successful switches was 3.70 ± 2.15 mgl dl, ex-
cluding the serum creatinine values of ~ pa-
tients who were on dialysiS at the time of f1(506 
conversion. The average creatinine after f1(506 
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~ sWitch was 2.84 ± 1.40 mg/dl, with all 11 grafts 
functioning. 
b) Primary Therapy 
FJ(506 was used from the outset with low doses 
of steroids to treat 65 recipients of primary kid-
rej"grafts. Of the tota166 renal allografts tr~K 
planted, all but 2, were cadaveric renal an~ 
~sK 35% of the 65 recipients were 
undergoing kidney retransplantation. 46% of 
the patients were classified as highly sensitized, 
with a panel reactive antibody (PRA) level 
>40%. 9% of the patients underwent renal 
transplantation in the face of a positive cytotox-
ic crossmatch using current or historical serum 
samples. 16 pediatric en bloc kidney allografts of 
the 66 allografts were used. 
The adual patient survival following kidney 
transplantation was 98%. One patient died 
fro~ a post-operative myocardial infarction, 3 
days following transplantation, in a diabetic pa-
tient with preexisting coronary artery disease. 
The corresponding overall graft survival was 
79%. In the patients who had a PRA <40%, the 
graft survival was 83%, while the graft survival 
in patients with PRA >40% was only 73%. The 
percentage of patients who have remained re-
jection free was 56%. The treatment for rejection 
episodes were generally accomplished with 
steroid boluses. As a reflection of the ease by 
which rejection was managed, the requirement 
for OI<T3 use was 29% for kidney patients. 
3. Hearl Transplantation 
a) Rescue Therapy 
Ten patients were converted from cyclosporine 
to FKS06 between 3 and 50 months post-
tra:&splant. The findings of persistent heart re-
jection defined by a >2+ grading of the endo-
myocardial biopsy by the Billingham criteria 
(14), included mononuclear cell infiltration, ar-
teritis and in some instances, interstitial fibro-
sis. All patients had faiJed conventional immu-
notherapy, including at least two courses of 
anti-lymphocyte preparations, and two courses 
of augmented steroids during the preceeding 
she months. The grading of endomyocardial bi-
opsies, prior to conversion to FK506, was 2.70 ± 
0.48. Using the same criteria, the mean value of 
the followup biopsies after FK506 was graded 
at 0.70 ± 0.67 (p<0.0l). The mean prednisone 
dose prior to FK506 conversion was 14 mg/ d, 
after FI<506 conversion this fell to 5.5 mg/d. 
Only one death occurred during the period of 
followup in a patient with disseminated asper-
gillosis. " 
b) Primary Therapy 
Thirty patients received FK506 from the outset 
following heart transplantation. 8 patients were 
on circulatory assist devices prior to heart 
transplantation. Followup ranged from 1 to 10 
months. Four patients have died, with an actual 
patient and graft survival of 87%. One patient 
with known pulmonary hypertension died on 
the third post-transplant day from right heart 
failure. One patient, with preexisting lung dis-
ease and bronchietasis, died from pulmonary 
infection, while two other patients died of sud-
den deaths, without a known cause of death. 
The rejection free rate within the first 90 days 
was 60%. Only one patient required OKT3. 
Heart function was excellent in all patients. The 
average left ventricular ejection fraction, deter-
mined by gated nuclear scans or echocardiogra-
phy, was 70% (range 58% to 75%). 
IV. DISCUSSION 
Cyc1osporine based immunosuppression signif-
icantly enhanced both patient and graft survi-
val in all solid organ transplants, when com-
pared to the era of azathioprine and steroids 
(16). Nevertheless, most centers experience an 
unacceptably high graft loss and patient losses 
are high in liver and heart transplantation. The 
most common complicating factor has been the 
development of rejection, occuring in over 70% 
of all cyclosporine treated patients. In addition, 
the sequelae of overimmunosuppression in at-
tempts to treat rejection, such as use of exces-
sive steroids, anti-lymphocyte preparations, are 
fraught with a high incidence of infectious com-
plications. It stands to reason that a baseline im-
munosuppressive agent which allows for less 
inddence of rejection, and easier treatment of 
rejection, would decrease both graft and patient 
loss. From the results of our preliminary stud-
ies presented here, the use of FI<506 in liver 
transplantation has these advantages. FI<506 
appears to not only decrease the absolute inci-
dence of rejection episodes, and allows for 
marked reduction in steroid doses, but makes 
the treabnent of rejection much simpler. 
The ability of a new immunosuppressive agent 
to be dose adjustable for treatment of acute and 
chronic rejection, would represent an important 
asset, which has only been ascribed to steroids 
in the past. FK506 can be used in this manner. 
In fact, the first response to a developing rejec-
tion, is to increase the dose of baseline FK506. 
In rescue therapy, the marked ability of FKS06 
to reverse acute rejection in both kidney and 
heart rejection, and both acute and chronic re-
jection in liver transplantation, has not been 
seen with any immunosuppressive agent in the 
past. While the mechanism by which FIG06 is 
able to do this, is not known, it would appear 
that it would entail mechanisms other than sim-
ply inhibition of IL-2 synthesis. The current sit-
utation with the Food and Drug Administration 
(FDA) regarding the use of FK506, is that it will 
require further substantiation of the efficacy of 
FIG06 in multicenter trials. Prospective, ran-
domized trials comparing FK506 therapy with 
cyclosporine based immunosuppression are 
currently underway. These studies will help 
identify areas in which FK506 may be more ad-
vantageous, or more disadvantageous, than 
current day immunosuppression. The initial 
studies will be carried out in liver transplanta-
tion, followed by studies in kidney transplanta-
tion. Heart transplantation and possibly bone 
marrow transplantation, will await the results 
of the initial liver and kidney multicenter trials. 
A well defined endpoint, other than patient or 
graft loss should be utilized, since the data pre-
sented here also suggests that a conversion to 
FK506 will allow for allografts in danger of be-
ing lost to rejection to be salvaged. Future trials 
examining the role of FK506 in solid organ allo-
graft rejection are being devised, either separ-
ately from the primary trials, or perhaps, as 
part of the primary trials. 
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